RAMP1 Antibody (3B9): sc-293438

RAMP1 Antibody (3B9) is a mouse monoclonal IgG2b kappa light chain antibody that detects RAMP1 protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-RAMP1 antibody (3B9) is available as the non-conjugated format. Receptor activity-modifying proteins (RAMPs) play a crucial role in modulating the function of calcitonin receptor-like receptors (CRLR), which are essential for various physiological processes, including vasodilation and pain modulation. RAMP1 specifically associates with CRLR to form a receptor for calcitonin-gene-related peptide (CGRP), a potent vasodilator involved in migraine pathophysiology. The interaction between RAMP1 and CRLR not only enhances the receptor′s affinity for CGRP but also influences downstream signaling pathways that regulate vascular tone and neuronal excitability. Understanding the function of RAMP1 is vital, as dysregulation of CGRP signaling has been implicated in several cardiovascular and neurological disorders. RAMP1 is predominantly expressed in the uterus, brain, and gastrointestinal tract, highlighting its importance in these tissues. The structural characteristics of RAMP1, including its type I receptor configuration with a single extracellular N-terminus and a cytoplasmic C-terminus, contribute to its functional specificity and interaction with CRLR, making RAMP1 a significant target for therapeutic interventions in diseases associated with CGRP signaling.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

RAMP1 Antibody (3B9) References:

1. The RAMP2/CRLR complex is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells.  |  Kamitani, S., et al. 1999. FEBS Lett. 448: 111-4. PMID: 10217420
2. A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1.  |  Bühlmann, N., et al. 1999. Endocrinology. 140: 2883-90. PMID: 10342881
3. The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor.  |  Fraser, NJ., et al. 1999. Mol Pharmacol. 55: 1054-9. PMID: 10347248
4. RAMPs: accessory proteins for seven transmembrane domain receptors.  |  Foord, SM. and Marshall, FH. 1999. Trends Pharmacol Sci. 20: 184-7. PMID: 10354609
5. Nociceptor neurons direct goblet cells via a CGRP-RAMP1 axis to drive mucus production and gut barrier protection.  |  Yang, D., et al. 2022. Cell. 185: 4190-4205.e25. PMID: 36243004
6. RAMP1 as a novel prognostic biomarker in pan-cancer and osteosarcoma.  |  Xie, L., et al. 2023. PLoS One. 18: e0292452. PMID: 37796823
7. The neuroimmune CGRP-RAMP1 axis tunes cutaneous adaptive immunity to the microbiota.  |  Kulalert, W., et al. 2024. Proc Natl Acad Sci U S A. 121: e2322574121. PMID: 38451947
8. RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway.  |  Tang, Y., et al. 2024. J Clin Transl Hepatol. 12: 357-370. PMID: 38638379
9. Nociceptor-to-macrophage communication through CGRP/RAMP1 signaling drives endometriosis-associated pain and lesion growth in mice.  |  Fattori, V., et al. 2024. Sci Transl Med. 16: eadk8230. PMID: 39504351
10. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.  |  McLatchie, LM., et al. 1998. Nature. 393: 333-9. PMID: 9620797
11. Expression of calcitonin receptor-like receptor and receptor-activity-modifying proteins in human cranial arteries.  |  Sams, A. and Jansen-Olesen, I. 1998. Neurosci Lett. 258: 41-4. PMID: 9876047
12. Desensitization of CGRP and adrenomedullin receptors in SK-N-MC cells: implications for the RAMP hypothesis.  |  Drake, WM., et al. 1999. Endocrinology. 140: 533-7. PMID: 9886866